抗葡萄球菌溶素 LSVT-1701 联合达托霉素治疗耐甲氧西林金黄色葡萄球菌引起的左侧感染性心内膜炎的疗效。
Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus.
机构信息
Lysovant Sciences, Inc., New York, New York, USA.
Department of Medicine, Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
出版信息
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0050821. doi: 10.1128/AAC.00508-21.
Abstract
We utilized the rabbit model of aortic valve infective endocarditis to examine the combined efficacy of the lysin LSVT-1701 plus daptomycin. The combination of LSVT-1701 plus daptomycin was highly effective at reducing methicillin-resistant Staphylococcus aureus (MRSA) counts in target tissue. When given for four daily doses, both lysin dose regimens in combination with daptomycin sterilized all target tissues. These findings suggest that LSVT-1701 warrants further clinical evaluation as an adjunctive therapy for the treatment of invasive MRSA infections.
摘要
我们利用兔感染性心内膜炎主动脉瓣模型来检验溶葡球菌素 LSVT-1701 与达托霉素联合应用的疗效。LSVT-1701 与达托霉素联合应用可高度降低靶组织中耐甲氧西林金黄色葡萄球菌（MRSA）的计数。每日给予 4 个剂量时，两种溶葡球菌素剂量方案联合达托霉素均使所有靶组织无菌。这些发现表明溶葡球菌素 LSVT-1701 有望作为一种辅助治疗药物，进一步临床评估其治疗侵袭性 MRSA 感染的效果。
相似文献
1
Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus.抗葡萄球菌溶素 LSVT-1701 联合达托霉素治疗耐甲氧西林金黄色葡萄球菌引起的左侧感染性心内膜炎的疗效。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0050821. doi: 10.1128/AAC.00508-21.
2
Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.通过超声心动图测定溶菌酶外切酶对耐甲氧西林金黄色葡萄球菌心内膜炎兔模型中心脏赘生物进展的影响。
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00482-20.
3
Emerging issues on endocarditis and the role in therapy of daptomycin plus fosfomycin.关于心内膜炎的新问题和磷霉素联合达托霉素在治疗中的作用。
Expert Rev Anti Infect Ther. 2023 Mar;21(3):281-293. doi: 10.1080/14787210.2023.2174969. Epub 2023 Feb 10.
4
High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.高剂量达托霉素联合磷霉素治疗耐甲氧西林敏感和耐甲氧西林金黄色葡萄球菌心内膜炎安全有效。
Antimicrob Agents Chemother. 2012 Aug;56(8):4511-5. doi: 10.1128/AAC.06449-11. Epub 2012 May 29.
5
Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.替拉万星对由达托霉素和耐甲氧西林金黄色葡萄球菌菌株引起的实验性主动脉瓣心内膜炎具有活性。
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01877-16. Print 2017 Feb.
6
In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis.治疗耐甲氧西林金黄色葡萄球菌心内膜炎期间体内获得的达托霉素耐药性。
Int J Infect Dis. 2013 Nov;17(11):e1076-7. doi: 10.1016/j.ijid.2013.02.019. Epub 2013 Apr 9.
7
Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.替拉万星治疗兔实验性主动脉瓣心内膜炎的疗效，该模型由耐甲氧西林金黄色葡萄球菌（daptomycin 不敏感株）引起。
Antimicrob Agents Chemother. 2012 Nov;56(11):5528-33. doi: 10.1128/AAC.00922-12. Epub 2012 Aug 13.
8
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.达托霉素对耐甲氧西林金黄色葡萄球菌所致实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2003 May;47(5):1714-8. doi: 10.1128/AAC.47.5.1714-1718.2003.
9
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.达托霉素对耐甲氧西林和糖肽类中介金黄色葡萄球菌引起的实验性心内膜炎治疗有效。
Antimicrob Agents Chemother. 2008 Jul;52(7):2538-43. doi: 10.1128/AAC.00510-07. Epub 2008 Apr 21.
10
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.达托霉素与万古霉素加庆大霉素治疗耐甲氧西林金黄色葡萄球菌所致菌血症和心内膜炎：耐甲氧西林分离株感染患者的亚组分析
J Antimicrob Chemother. 2008 Dec;62(6):1413-21. doi: 10.1093/jac/dkn372. Epub 2008 Sep 8.
引用本文的文献
1
Phage Therapy, a Salvage Treatment for Multidrug-Resistant Bacteria Causing Infective Endocarditis.噬菌体疗法：一种针对引起感染性心内膜炎的多重耐药细菌的挽救性治疗方法
Biomedicines. 2023 Oct 22;11(10):2860. doi: 10.3390/biomedicines11102860.
2
Native valve, prosthetic valve, and cardiac device-related infective endocarditis: A review and update on current innovative diagnostic and therapeutic strategies.自体瓣膜、人工瓣膜及心脏装置相关感染性心内膜炎：当前创新诊断与治疗策略的综述与更新
Front Cell Dev Biol. 2022 Oct 3;10:995508. doi: 10.3389/fcell.2022.995508. eCollection 2022.
3
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.分析治疗耐药菌感染的临床药物研发管线：尽管取得了进展，但仍需采取更多行动。
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0199121. doi: 10.1128/AAC.01991-21. Epub 2022 Jan 10.
4
A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects.一项评估健康成年受试者单剂量和多剂量抗葡萄球菌溶菌酶 LSVT-1701 给药后的安全性和药代动力学的 I 期研究。
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0184221. doi: 10.1128/AAC.01842-21. Epub 2022 Jan 10.
本文引用的文献
1
Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.通过超声心动图测定溶菌酶外切酶对耐甲氧西林金黄色葡萄球菌心内膜炎兔模型中心脏赘生物进展的影响。
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00482-20.
2
Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection.噬菌体溶素 SAL200 联合抗生素对金黄色葡萄球菌感染的影响。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.00731-18. Print 2018 Oct.
3
Infective endocarditis.感染性心内膜炎。
Nat Rev Dis Primers. 2016 Sep 1;2:16059. doi: 10.1038/nrdp.2016.59.
4
Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period.基于噬菌体溶菌酶的候选药物SAL200在猴子体内的药代动力学及其合适的静脉给药周期。
Clin Exp Pharmacol Physiol. 2016 Oct;43(10):1013-6. doi: 10.1111/1440-1681.12613.
5
Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.金黄色葡萄球菌感染：流行病学、病理生理学、临床表现及管理
Clin Microbiol Rev. 2015 Jul;28(3):603-61. doi: 10.1128/CMR.00134-14.
6
Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient.含重组噬菌体溶菌酶SAL-1作为药物成分的静脉注射用SAL200的临床前安全性评价
Antimicrob Agents Chemother. 2014;58(4):2084-8. doi: 10.1128/AAC.02232-13. Epub 2014 Jan 21.
7
Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1.SAL-1 预制重组噬菌体溶菌素的抗菌特性。
Int J Antimicrob Agents. 2013 Feb;41(2):156-61. doi: 10.1016/j.ijantimicag.2012.10.011. Epub 2012 Dec 28.
8
Differential Adaptations of Methicillin-Resistant Staphylococcus aureus to Serial In Vitro Passage in Daptomycin: Evolution of Daptomycin Resistance and Role of Membrane Carotenoid Content and Fluidity.耐甲氧西林金黄色葡萄球菌对达托霉素连续体外传代的差异适应性：达托霉素耐药性的演变以及膜类胡萝卜素含量和流动性的作用
Int J Microbiol. 2012;2012:683450. doi: 10.1155/2012/683450. Epub 2012 Aug 16.
9
Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌体外筛选的达托霉素耐药菌株的细胞膜特性分析
Antimicrob Agents Chemother. 2009 Jun;53(6):2312-8. doi: 10.1128/AAC.01682-08. Epub 2009 Mar 30.
10
Role of mgrA and sarA in methicillin-resistant Staphylococcus aureus autolysis and resistance to cell wall-active antibiotics.MgrA和SarA在耐甲氧西林金黄色葡萄球菌自溶及对细胞壁活性抗生素耐药中的作用。
J Infect Dis. 2009 Jan 15;199(2):209-18. doi: 10.1086/595740.
Zotero 插件